Concern over pricy medication 'just headlines' By: CNBC.com News March 24, 2014 at 13:50 PM EDT Gilead Sciences' high-priced drug Sovaldi is under lawmakers' scrutiny. But biotech analyst Christopher Raymond of R.W. Baird says there's a bigger problem. Read More >> Related Stocks: Alexion Pharmaceuticals Celgene Corp Gilead Sciences Regeneron Pharmaceuticals Twitter, Inc.